Find Ibrexafungerp Citrate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Scy-078 citrate, M4nu2sdx3e, Ibrexafungerp citrate [usan], 1965291-08-0, Ibrexafungerp citrate (usan), Brexafemme
Molecular Formula
C50H75N5O11
Molecular Weight
922.2  g/mol
InChI Key
WKIRTJACGBEXBZ-FQGZCCSZSA-N
FDA UNII
M4NU2SDX3E

Ibrexafungerp Citrate
1 2D Structure

Ibrexafungerp Citrate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1R,5S,6R,7R,10R,11R,14R,15S,20R,21R)-21-[(2R)-2-amino-2,3,3-trimethylbutoxy]-5,7,10,15-tetramethyl-7-[(2R)-3-methylbutan-2-yl]-20-(5-pyridin-4-yl-1,2,4-triazol-1-yl)-17-oxapentacyclo[13.3.3.01,14.02,11.05,10]henicos-2-ene-6-carboxylic acid;2-hydroxypropane-1,2,3-tricarboxylic acid
2.1.2 InChI
InChI=1S/C44H67N5O4.C6H8O7/c1-27(2)28(3)39(7)18-19-41(9)30-12-13-33-40(8)23-52-25-44(33,31(30)14-17-42(41,10)34(39)37(50)51)22-32(35(40)53-24-43(11,45)38(4,5)6)49-36(47-26-48-49)29-15-20-46-21-16-29;7-3(8)1-6(13,5(11)12)2-4(9)10/h14-16,20-21,26-28,30,32-35H,12-13,17-19,22-25,45H2,1-11H3,(H,50,51);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t28-,30+,32-,33+,34-,35+,39-,40-,41-,42+,43+,44+;/m1./s1
2.1.3 InChI Key
WKIRTJACGBEXBZ-FQGZCCSZSA-N
2.1.4 Canonical SMILES
CC(C)C(C)C1(CCC2(C3CCC4C5(COCC4(C3=CCC2(C1C(=O)O)C)CC(C5OCC(C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
2.1.5 Isomeric SMILES
C[C@H](C(C)C)[C@]1(CC[C@@]2([C@H]3CC[C@H]4[C@]5(COC[C@]4(C3=CC[C@]2([C@@H]1C(=O)O)C)C[C@H]([C@@H]5OC[C@@](C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C.C(C(=O)O)C(CC(=O)O)(C(=O)O)O
2.2 Other Identifiers
2.2.1 UNII
M4NU2SDX3E
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Brexafemme

2. Ibrexafungerp

3. Mk-3118

4. Scy-078

2.3.2 Depositor-Supplied Synonyms

1. Scy-078 Citrate

2. M4nu2sdx3e

3. Ibrexafungerp Citrate [usan]

4. 1965291-08-0

5. Ibrexafungerp Citrate (usan)

6. Brexafemme

7. Unii-m4nu2sdx3e

8. Chembl4298168

9. Glxc-26020

10. Ibrexafungerp Citrate [who-dd]

11. Ibrexafungerp Citrate [orange Book]

12. D11545

13. (1s,4ar,6as,7r,8r,10ar,10br,12ar,14r,15r)-15-((2r)- 2-amino-2,3,3-trimethylbutoxy)-1,6a,8,10a-tetramethyl-8- ((2r)-3-methylbutan-2-yl)-14-(5-(pyridin-4-yl)-1h-1,2,4- Triazol-1-yl)-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-2h,4h-1,4a-propanophenanthro(1,2-c)pyran-7-carboxylic Acid Compound With 2-hydroxypropane-1,2,3-tricarboxylic Acid (1:1)

14. 4h-1,4a-propano-2h-phenanthro(1,2-c)pyran-7-carboxylic Acid, 15-((2r)-2-amino-2,3,3-trimethylbutoxy)-8-((1r)-1,2-dimethylpropyl)-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-14-(5-(4-pyridinyl)-1h-1,2,4-triazol-1-yl)-, (1s,4ar,6as

15. 4h-1,4a-propano-2h-phenanthro(1,2-c)pyran-7-carboxylic Acid, 15-((2r)-2-amino-2,3,3-trimethylbutoxy)-8-((1r)-1,2-dimethylpropyl)-1,6,6a,7,8,9,10,10a,10b,11,12,12a-dodecahydro-1,6a,8,10a-tetramethyl-14-(5-(4-pyridinyl)-1h-1,2,4-triazol-1-yl)-, (1s,4ar,6as,7r,8r,10ar,10br,12ar,14r,15r)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1)

2.4 Create Date
2019-03-24
3 Chemical and Physical Properties
Molecular Weight 922.2 g/mol
Molecular Formula C50H75N5O11
Hydrogen Bond Donor Count6
Hydrogen Bond Acceptor Count15
Rotatable Bond Count14
Exact Mass921.54630823 g/mol
Monoisotopic Mass921.54630823 g/mol
Topological Polar Surface Area258 Ų
Heavy Atom Count66
Formal Charge0
Complexity1650
Isotope Atom Count0
Defined Atom Stereocenter Count12
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antifungal Agents

Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)


API SUPPLIERS

read-more
read-more

01

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT arrow-down
Metrochem

02

Omgene Life Sciences Pvt. Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Omgene Company Banner

03

BrightGene Bio-Medical Technology ...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BIO Partnering at JPM
Not Confirmed
arrow

BrightGene Bio-Medical Technology ...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BIO Partnering at JPM
Not Confirmed
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content

Ibrexafungerp Citrate

About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...

Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product groups and has been approved by ISO 9001-2015, USFDA, WHO GMP, Cofepris & Japanese authorities. Metrochem’s in-depth industry knowledge, & hi-tech & advanced infrastructure, helps it provide quality products to its customers. Note: None of the products will be supplied to the countries where this could conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer
Metrochem

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

Flag India
Digital Content Digital Content

Ibrexafungerp Citrate

About the Company : Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integ...

Omgene Life Sciences Pvt. Ltd. is an R&D-driven biopharmaceutical company specializing in biopharmaceuticals, peptides, semi-synthetic, and synthetic actives. As a vertically integrated company, we focus on developing high-quality formulations based on in-house-produced actives. With GMP-certified facilities and partnerships with contract manufacturers, we excel in formulation development for injectables, lyophilized injectables, complex generics, and oral peptide delivery systems, ensuring affordable, top-quality medicines. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Omgene Company Banner

03

BIO Partnering at JPM
Not Confirmed
arrow
arrow
BIO Partnering at JPM
Not Confirmed

Ibrexafungerp Citrate

About the Company : BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special gener...

BrightGene Bio-Medical Technology Co., Ltd. is a research driven biopharmaceutical company that engages in the R&D and manufacturing of innovative medicine as well as special generic APIs and FDFs with primary strategic focus on the regulated market. We have an exciting and very promising innovative pipeline including immuno-oncological therapeutic agents, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumor, novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastasis.
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Through the licensing deal for Ibrexafungerp Citrate, the agreement aims to advance treatment for vulvovaginal candidiasis by targeting 1,3-beta-glucan synthase.


Lead Product(s): Ibrexafungerp Citrate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Brexafemme

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: GSK

Deal Size: $593.0 million Upfront Cash: $90.0 million

Deal Type: Licensing Agreement November 19, 2025

blank

01

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Through the licensing deal for Ibrexafungerp Citrate, the agreement aims to advance treatment for vulvovaginal candidiasis by targeting 1,3-beta-glucan synthase.

Product Name : Brexafemme

Product Type : Miscellaneous

Upfront Cash : $90.0 million

November 19, 2025

blank

Details:

Through the licensing deal for Ibrexafungerp Citrate, the agreement aims to advance treatment for invasive candidiasis by targeting 1,3-beta-glucan synthase.


Lead Product(s): Ibrexafungerp Citrate

Therapeutic Area: Infections and Infectious Diseases Brand Name: Brexafemme

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: GSK

Deal Size: $593.0 million Upfront Cash: $90.0 million

Deal Type: Licensing Agreement October 15, 2025

blank

02

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Through the licensing deal for Ibrexafungerp Citrate, the agreement aims to advance treatment for invasive candidiasis by targeting 1,3-beta-glucan synthase.

Product Name : Brexafemme

Product Type : Miscellaneous

Upfront Cash : $90.0 million

October 15, 2025

blank

Details:

Ibrexafungerp is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Candidiasis, Vulvovaginal.


Lead Product(s): Ibrexafungerp Citrate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 01, 2025

blank

03

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Ibrexafungerp is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Candidiasis, Vulvovaginal.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 01, 2025

blank

Details:

Under the agreement, GSK has the rights to develop GSK5458448/SCY-078 (ibrexafungerp), a novel oral glucan synthase inhibitor and commercialize Brexafemme in all countries except the greater China.


Lead Product(s): Ibrexafungerp Citrate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Brexafemme

Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous

Sponsor: GSK

Deal Size: $593.0 million Upfront Cash: $90.0 million

Deal Type: Licensing Agreement July 23, 2024

blank

04

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Under the agreement, GSK has the rights to develop GSK5458448/SCY-078 (ibrexafungerp), a novel oral glucan synthase inhibitor and commercialize Brexafemme in all countries except the greater China.

Product Name : Brexafemme

Product Type : Miscellaneous

Upfront Cash : $90.0 million

July 23, 2024

blank

Details:

GSK acquired the rights to develop and commercialize GSK5458448 (ibrexafungerp), a glucan synthase inhibitor, and market Brexafemme for antifungal indications outside China.


Lead Product(s): Ibrexafungerp Citrate,Caspofungin

Therapeutic Area: Infections and Infectious Diseases Brand Name: Brexafemme

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: GSK

Deal Size: $401.0 million Upfront Cash: $90.0 million

Deal Type: Licensing Agreement January 03, 2024

blank

05

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : GSK acquired the rights to develop and commercialize GSK5458448 (ibrexafungerp), a glucan synthase inhibitor, and market Brexafemme for antifungal indications outside China.

Product Name : Brexafemme

Product Type : Miscellaneous

Upfront Cash : $90.0 million

January 03, 2024

blank

Details:

Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, approved for vulvovaginal candidiasis and RVVC, is being develop in phase 3 trials for the potential treatment of invasive candidiasis.


Lead Product(s): Ibrexafungerp Citrate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Brexafemme

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Hansoh Pharma

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 20, 2023

blank

06

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, approved for vulvovaginal candidiasis and RVVC, is being develop in phase 3 trials for the potential treatment of invasive candidiasis.

Product Name : Brexafemme

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 20, 2023

blank

Details:

Under the agreement GSK gains right to commercialize Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, for vulvovaginal candidiasis and RVVC while continuing to develop ibrexafungerp, in phase 3 trials for the potential treatment of invasive candidiasis.


Lead Product(s): Ibrexafungerp Citrate,Caspofungin

Therapeutic Area: Infections and Infectious Diseases Brand Name: Brexafemme

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: GSK

Deal Size: $593.0 million Upfront Cash: $90.0 million

Deal Type: Licensing Agreement June 21, 2023

blank

07

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Under the agreement GSK gains right to commercialize Brexafemme (ibrexafungerp), a novel glucan synthase inhibitor, for vulvovaginal candidiasis and RVVC while continuing to develop ibrexafungerp, in phase 3 trials for the potential treatment of invasive...

Product Name : Brexafemme

Product Type : Miscellaneous

Upfront Cash : $90.0 million

June 21, 2023

blank

Details:

Under the agreement, GSK has the rights to develop ibrexafungerp, a novel oral glucan synthase inhibitor with a broad spectrum of activity and commercialize Brexafemme (ibrexafungerp tablets) in all countries except the greater China region.


Lead Product(s): Ibrexafungerp Citrate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Brexafemme

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: GSK

Deal Size: $593.0 million Upfront Cash: $90.0 million

Deal Type: Licensing Agreement May 12, 2023

blank

08

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Under the agreement, GSK has the rights to develop ibrexafungerp, a novel oral glucan synthase inhibitor with a broad spectrum of activity and commercialize Brexafemme (ibrexafungerp tablets) in all countries except the greater China region.

Product Name : Brexafemme

Product Type : Miscellaneous

Upfront Cash : $90.0 million

May 12, 2023

blank

Details:

Under the agreement, GSK gains rights to commercialise Brexafemme, a first-in-class antifungal for the treatment of VVC and for reduction in the incidence of RVVC while continuing to develop ibrexafungerp, which is in phase III trials for the potential treatment of IC.


Lead Product(s): Ibrexafungerp Citrate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Brexafemme

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: GSK

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement March 30, 2023

blank

09

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Under the agreement, GSK gains rights to commercialise Brexafemme, a first-in-class antifungal for the treatment of VVC and for reduction in the incidence of RVVC while continuing to develop ibrexafungerp, which is in phase III trials for the potential t...

Product Name : Brexafemme

Product Type : Miscellaneous

Upfront Cash : Undisclosed

March 30, 2023

blank

Details:

Ibrexafungerp is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Mycoses.


Lead Product(s): Ibrexafungerp Citrate,Inapplicable

Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 29, 2022

blank

10

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Scynexis

U.S.A
arrow
BIO Partnering at JPM
Not Confirmed

Details : Ibrexafungerp is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Mycoses.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 29, 2022

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

GSK

United Kingdom
BIO Partnering at JPM
Not Confirmed
arrow

GSK

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

IBREXAFUNGERP CITRATE

Brand Name : BREXAFEMME

Dosage Form : TABLET;ORAL

Dosage Strength : EQ 150MG BASE

Packaging :

Approval Date : 2021-06-01

Application Number : 214900

Regulatory Info : RX

Registration Country : USA

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

read-more
read-more

01

arrow
BIO Partnering at JPM
Not Confirmed

GLAXOSMITHKLINE

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

IBREXAFUNGERP CITRATE

US Patent Number : 11534433

Drug Substance Claim :

Drug Product Claim :

Application Number : 214900

Patent Use Code : U-3159

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-06-10

blank

02

arrow
BIO Partnering at JPM
Not Confirmed

GLAXOSMITHKLINE

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

IBREXAFUNGERP CITRATE

US Patent Number : 11534433

Drug Substance Claim :

Drug Product Claim :

Application Number : 214900

Patent Use Code : U-3508

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2039-06-10

blank

03

arrow
BIO Partnering at JPM
Not Confirmed

GLAXOSMITHKLINE

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

IBREXAFUNGERP CITRATE

US Patent Number : 8188085

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 214900

Patent Use Code : U-3159

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2030-08-28

blank

04

arrow
BIO Partnering at JPM
Not Confirmed

GLAXOSMITHKLINE

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

IBREXAFUNGERP CITRATE

US Patent Number : 10370406

Drug Substance Claim :

Drug Product Claim :

Application Number : 214900

Patent Use Code : U-3159

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-01-19

blank

05

arrow
BIO Partnering at JPM
Not Confirmed

GLAXOSMITHKLINE

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

IBREXAFUNGERP CITRATE

US Patent Number : 10927142

Drug Substance Claim : Y

Drug Product Claim :

Application Number : 214900

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-01-19

blank

06

arrow
BIO Partnering at JPM
Not Confirmed

GLAXOSMITHKLINE

United Kingdom
arrow
BIO Partnering at JPM
Not Confirmed

IBREXAFUNGERP CITRATE

US Patent Number : 10174074

Drug Substance Claim : Y

Drug Product Claim : Y

Application Number : 214900

Patent Use Code :

Delist Requested :

Patent Use Description :

Patent Expiration Date : 2035-01-19

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Looking for 1965291-08-0 / Ibrexafungerp Citrate API manufacturers, exporters & distributors?

Ibrexafungerp Citrate manufacturers, exporters & distributors 1

48

PharmaCompass offers a list of Ibrexafungerp Citrate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ibrexafungerp Citrate manufacturer or Ibrexafungerp Citrate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ibrexafungerp Citrate manufacturer or Ibrexafungerp Citrate supplier.

PharmaCompass also assists you with knowing the Ibrexafungerp Citrate API Price utilized in the formulation of products. Ibrexafungerp Citrate API Price is not always fixed or binding as the Ibrexafungerp Citrate Price is obtained through a variety of data sources. The Ibrexafungerp Citrate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Ibrexafungerp Citrate

Synonyms

Scy-078 citrate, M4nu2sdx3e, Ibrexafungerp citrate [usan], 1965291-08-0, Ibrexafungerp citrate (usan), Brexafemme

Cas Number

1965291-08-0

Unique Ingredient Identifier (UNII)

M4NU2SDX3E

Ibrexafungerp Citrate Manufacturers

A Ibrexafungerp Citrate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ibrexafungerp Citrate, including repackagers and relabelers. The FDA regulates Ibrexafungerp Citrate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ibrexafungerp Citrate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Ibrexafungerp Citrate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Ibrexafungerp Citrate Suppliers

A Ibrexafungerp Citrate supplier is an individual or a company that provides Ibrexafungerp Citrate active pharmaceutical ingredient (API) or Ibrexafungerp Citrate finished formulations upon request. The Ibrexafungerp Citrate suppliers may include Ibrexafungerp Citrate API manufacturers, exporters, distributors and traders.

click here to find a list of Ibrexafungerp Citrate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Ibrexafungerp Citrate GMP

Ibrexafungerp Citrate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Ibrexafungerp Citrate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ibrexafungerp Citrate GMP manufacturer or Ibrexafungerp Citrate GMP API supplier for your needs.

Ibrexafungerp Citrate CoA

A Ibrexafungerp Citrate CoA (Certificate of Analysis) is a formal document that attests to Ibrexafungerp Citrate's compliance with Ibrexafungerp Citrate specifications and serves as a tool for batch-level quality control.

Ibrexafungerp Citrate CoA mostly includes findings from lab analyses of a specific batch. For each Ibrexafungerp Citrate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Ibrexafungerp Citrate may be tested according to a variety of international standards, such as European Pharmacopoeia (Ibrexafungerp Citrate EP), Ibrexafungerp Citrate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ibrexafungerp Citrate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty